High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production inEnterobacteriaceaeBloodstream Infections at a Major Cancer Center: Table 1.-Reference-Cited by-同舟云学术

High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production inEnterobacteriaceaeBloodstream Infections at a Major Cancer Center: Table 1.

Published:2016-06-16 Issue:7 Volume:63 Page:954-958
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:Clin Infect Dis.

Author:

Aitken Samuel L.,Tarrand Jeffrey J.,Deshpande Lalitagauri M.,Tverdek Frank P.,Jones Anne L.,Shelburne Samuel A.,Prince Randall A.,Bhatti Micah M.,Rolston Kenneth V. I.,Jones Ronald N.,Castanheira Mariana,Chemaly Roy F.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/63/7/954/16789293/ciw398.pdf

Reference18 articles.

1. Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria;Dortet;Biomed Res Int,2014

2. New Delhi Metallo-β-Lactamase–Producing Carbapenem-ResistantEscherichia coliAssociated With Exposure to Duodenoscopes

3. New Delhi Metallo-β-Lactamase-1–ProducingKlebsiella pneumoniae, Florida, USA1

4. Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013

5. NDM-producing carbapenem-resistant Enterobacteriaceae (CRE) isolates reported to the Centers for Disease Control and Prevention (CDC) as of January 2015, by state. Available at: http://www.cdc.gov/hai/organisms/cre/TrackingCRE.html#CREmapNDM . Accessed 24 June 2016.

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vitro mimicry of in vivo KPC mutations by ceftazidime-avibactam: phenotypes, mechanisms, genetic structure and kinetics of enzymatic hydrolysis;Emerging Microbes & Infections;2024-06-04

2. A Case of New Delhi Metallo-ß-Lactamase-Producing Enterobacter and a Review of Cases in the United States From January 2009 to September 2022;Cureus;2024-05-13

3. Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis With Sulbactam-Durlobactam;Clinical Infectious Diseases;2024-04-17

4. Clinical distribution of carbapenem genotypes and resistance to ceftazidime-avibactam in Enterobacteriaceae bacteria;Frontiers in Cellular and Infection Microbiology;2024-03-20

5. Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185;mBio;2024-02-14